299 related articles for article (PubMed ID: 27487294)
21. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.
De Bock K; Cauwenberghs S; Carmeliet P
Curr Opin Genet Dev; 2011 Feb; 21(1):73-9. PubMed ID: 21106363
[TBL] [Abstract][Full Text] [Related]
22. Antiangiogenic cancer therapy.
Cao Y
Semin Cancer Biol; 2004 Apr; 14(2):139-45. PubMed ID: 15018898
[TBL] [Abstract][Full Text] [Related]
23. Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review.
Ahmed ZSO; Golovoy M; Abdullah Y; Ahmed RSI; Dou QP
Recent Pat Anticancer Drug Discov; 2021; 16(2):161-186. PubMed ID: 34132186
[TBL] [Abstract][Full Text] [Related]
24. Off-tumor target--beneficial site for antiangiogenic cancer therapy?
Cao Y
Nat Rev Clin Oncol; 2010 Oct; 7(10):604-8. PubMed ID: 20683436
[TBL] [Abstract][Full Text] [Related]
25. [Angiogenesis and antiangiogenic cancer therapy].
Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
[TBL] [Abstract][Full Text] [Related]
26. Angiogenesis inhibitors in combinatorial approaches.
Nowak-Sliwinska P; Griffioen AW
Angiogenesis; 2017 May; 20(2):183-184. PubMed ID: 28382510
[No Abstract] [Full Text] [Related]
27. Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation.
Wang JC; Li GY; Wang B; Han SX; Sun X; Jiang YN; Shen YW; Zhou C; Feng J; Lu SY; Liu JL; Wang MD; Liu PJ
J Exp Clin Cancer Res; 2019 Jun; 38(1):235. PubMed ID: 31164151
[TBL] [Abstract][Full Text] [Related]
28. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
29. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y
Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
[TBL] [Abstract][Full Text] [Related]
30. Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.
Ribatti D
Cancer Treat Rev; 2011 Aug; 37(5):344-52. PubMed ID: 21435792
[TBL] [Abstract][Full Text] [Related]
31. Modulating the tumor microenvironment to improve radiotherapy.
Maity A
Retina; 2009 Jun; 29(6 Suppl):S32-3. PubMed ID: 19553796
[TBL] [Abstract][Full Text] [Related]
32. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
Roukos DH; Tzakos A; Zografos G
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
[No Abstract] [Full Text] [Related]
33. The therapeutic potential of novel antiangiogenic therapies.
Scappaticci FA
Expert Opin Investig Drugs; 2003 Jun; 12(6):923-32. PubMed ID: 12783597
[TBL] [Abstract][Full Text] [Related]
34. Clinical implications of angiogenesis in cancers.
Pang RW; Poon RT
Vasc Health Risk Manag; 2006; 2(2):97-108. PubMed ID: 17319453
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor: biology and therapeutic applications.
Ho QT; Kuo CJ
Int J Biochem Cell Biol; 2007; 39(7-8):1349-57. PubMed ID: 17537667
[TBL] [Abstract][Full Text] [Related]
36. Antiangiogenic Effect of Flavonoids and Chalcones: An Update.
Mirossay L; Varinská L; Mojžiš J
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271940
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor as a target for antiangiogenic therapy.
Gordon MS
J Clin Oncol; 2000 Nov; 18(21 Suppl):45S-6S. PubMed ID: 11060326
[No Abstract] [Full Text] [Related]
38. Anti-angiogenic therapies in cancer: achievements and open questions.
Ruegg C; Mutter N
Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
[TBL] [Abstract][Full Text] [Related]
39. Angiogenesis in Colorectal Cancer: Antibodies.
Chan E
Cancer J; 2016; 22(3):179-81. PubMed ID: 27341595
[TBL] [Abstract][Full Text] [Related]
40. Antiangiogenic therapy and surgical practice.
John AR; Bramhall SR; Eggo MC
Br J Surg; 2008 Mar; 95(3):281-93. PubMed ID: 18278790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]